CD63 and cancer: Importantly, we validated that many of these molecular features are enriched in EVs derived from multiple cell types—including cancer cells and primary fibroblasts—as well as across CD9-, CD63- and CD81-positive pEVs, suggesting they are not artefacts of averaging but representative of fundamental EV-associated signatures.